Jinxi Ding
Datos Biográficos
| ID | 7828284 |
|---|---|
| NOMBRE | Jinxi Ding |
| NOMBRES | Jinxi |
| APELLIDO | Ding |
| FIRMA | DING J |
| AFILIACIONES | China Pharmaceutical University |
| ORCID | 0009-0003-8563-2540 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 3 |
| TOTAL DE CITAS | 0 |
| OBRAS COMO AUTOR | 3 |
| OBRAS COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2022 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2026 |
| ÍNDICE H | 0 |
Impact of elevated pooling levels in basic medical insurance on insured individuals' inpatient service utilization—An equity analysis
Background: China has continuously promoted the transition of basic medical insurance from municipal-level pooling to provincial-level pooling to strengthen fund risk resilience, mutual-aid capacity, and benefit equalization. Although existing studies suggest that higher pooling levels may influence healthcare utilization, limited micro-level evidence exists on how provincial-level pooling of the Basic Medical Insurance Scheme for Urban and Rural…
Analysis of affordability differences for rare diseases in China
Although China has made progress in improving the affordability of rare diseases, significant differences persist between cities and diseases. The study suggests the optimization of the BMI system and explores independent funds and innovative insurance models to enhance the affordability of rare diseases, particularly those with extremely high treatment costs
Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
Objective This study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China. Materials and methods Cancer drugs marketed before June 30 th , 2021 with publicly available technical review reports for application of drug registration on Center for Drug Evaluation (CDE) website were reviewed. The trial design characteristics and relevant clinical outcomes [e.…
Sin obras prominentes en esta página.
Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
Objective This study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China. Materials and methods Cancer drugs marketed before June 30 th , 2021 with publicly available technical review reports for application of drug registration on Center for Drug Evaluation (CDE) website were reviewed. The trial design characteristics and relevant clinical outcomes [e.…
Analysis of affordability differences for rare diseases in China
Although China has made progress in improving the affordability of rare diseases, significant differences persist between cities and diseases. The study suggests the optimization of the BMI system and explores independent funds and innovative insurance models to enhance the affordability of rare diseases, particularly those with extremely high treatment costs
Impact of elevated pooling levels in basic medical insurance on insured individuals' inpatient service utilization—An equity analysis
Background: China has continuously promoted the transition of basic medical insurance from municipal-level pooling to provincial-level pooling to strengthen fund risk resilience, mutual-aid capacity, and benefit equalization. Although existing studies suggest that higher pooling levels may influence healthcare utilization, limited micro-level evidence exists on how provincial-level pooling of the Basic Medical Insurance Scheme for Urban and Rural…
Health care (3 obras) · Business (2 obras) · China (2 obras) · Health Systems, Economic Evaluations, Quality of Life (2 obras) · Healthcare Systems and Reforms (2 obras) · Medicine (2 obras) · Reimbursement (2 obras) · Actuarial science (1 obra) · Cancer (1 obra) · Cancer drugs (1 obra)